profit from every €100 of sales.
€0€100
Dermapharm
€34.95-9.46% today
-5.5% since Dec 19, 25
1-year low €34.701-year high €51.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €13.08 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Dermapharm sold, what it kept, and what it did with the cash.
Sales went from €1.02 billion in 2022 to €1.16 billion in 2025, with €132 million of profit last year.
SalesProfit
Dermapharm handed back 26% of the cash it generated last year.
€48M
Free cash flow 2025€187M
Bought back its own shares–
Paid as dividends€48M
Cash vs. debt€203M vs. €1.1B
Dermapharm vs. similar companies
Dermapharm grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Dermapharm | 13.1× · Cheap | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Dermapharm's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,025 | 1,135 | 1,181 | 1,165 | |
| 661 | 719 | 767 | 783 | |
| 242 | 180 | 215 | 227 | |
| 330 | 266 | 321 | 325 | |
| 134 | 62 | 114 | 132 | |
| 2.49 | 1.16 | 2.11 | 2.46 | |
| 64.5% | 63.3% | 65.0% | 67.2% | |
| 23.6% | 15.9% | 18.2% | 19.5% | |
| 13.1% | 5.5% | 9.6% | 11.4% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,413 | 2,161 | 2,080 | 2,187 |
| Cash | 150 | 159 | 121 | 203 |
| Total debt | 5 | 1,080 | 980 | 1,052 |
| Total liabilities | 880 | 1,616 | 1,472 | 1,496 |
| 532 | 539 | 604 | 694 | |
| 54 | 54 | 54 | 54 | |
| 29.8% | 7.0% | 10.2% | 9.3% | |
| 25.3% | 11.6% | 18.8% | 19.1% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 289 | 219 | 201 | 229 | |
| 39 | 42 | 38 | 42 | |
| 250 | 178 | 163 | 187 | |
| Dividends paid | 117 | 57 | 47 | 48 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 13.1×
- –
- –
- 3.4×
- 1.5×
- 9.3×
- 7.9×
- 10.8%
- 7.6%
- 2.8%
Profitability
- 67.2%
- 19.5%
- 11.4%
- –
- 9.3%
- 14.1%
- –
- –
- –
- –
Growth
- +4.4%
- −0.4%
- –
- –
- +0.0%
Financial health
- 2.6×
- 1.52
- –
- 4.8×
- 2.05
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 34%of 952
Top 25%of 883
Top 16%of 576
Bottom 25%of 870
Top 6%of 985
2.8%of the share price, paid each year
On $1,000 invested$28a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
36.6% of its profit
Room to growStretchedMore than it earns: 25.9%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
63Pass
Benjamin Graham
56No pass
Philip Fisher
56No pass
Peter Lynch
22No pass
Joel Greenblatt
44No pass
Charlie Munger
53No pass
Terry Smith
53No pass
Questions about Dermapharm
Is Dermapharm a good stock to buy?
A solid business, and the price looks low. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Dermapharm AI analysis
What does Dermapharm do?
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. It is in Drug Manufacturers - Specialty & Generic, based in Grünwald, Germany, with 3,503 employees.
Does Dermapharm pay a dividend?
Yes. At today's price the dividend is 2.8% a year, about 37% of its yearly profit. In 2025 it paid out €48.5 million in dividends.
Is Dermapharm stock halal?
No. Dermapharm does not pass our halal screen: its debt is 61% of its market value, at or above the 33% limit. How we check
Who are Dermapharm's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Dermapharm's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.